Esophageal, gastric and duodenal Crohn’s disease in the biologic era: Results from a retrospective observational nationwide study of GETECCU

Key Points

• This study investigates whether upper gastrointestinal involvement in Crohn’s disease affects the need for immunosuppressive therapy.
• Conducted a retrospective observational study across a nationwide cohort.
• Analyzed therapeutic needs in patients with esophageal, gastric, and duodenal Crohn's disease.
• Compared immunosuppressive requirements with those of other Crohn's disease patients.
• No significant variation in immunosuppressive therapy needs was observed for patients with upper GI involvement.
• Therapeutic requirements remained consistent across different types of Crohn's disease.